Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.
Sabrina Serani
Sabrina Serani is the assistant managing editor for Targeted Oncology.
Articles by Sabrina Serani
Results from a phase 1/2a trial showed that plixorafenib had potential regarding safety and efficacy in BRAF-mutated solid tumors, especially in primary central nervous system tumors.
The combination of olaptesed pegol, bevacizumab, and radiotherapy showed an improvement in overall survival among patients with glioblastoma, according to findings from a phase 1/2 study.
The use of poly ADP ribose polymerase inhibitors in the treatment of metastatic castration-resistant prostate cancer were associated with an increased risk of hematological adverse events.
Enzalutamide is the first and only androgen receptor signaling inhibitor approved by the FDA in this intent-to-treat population.
Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
The FDA’s Oncologic Drugs Advisory Committee discussed delays that can occur when drugs are granted accelerated approval, and the post-approval confirmatory trials of pralatrexate and belinostat for peripheral T-cell lymphoma.
In a phase 3 trial, concurrently administered durvalumab and platinum-based chemoradiotherapy did not increase progression-free survival in stage III unresectable non–small cell lung cancer.
The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.
Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.
This companion diagnostic tool, which is already approved for use in 5 other cancer types, identifies patients who may be suited for treatment with pembrolizumab.
A recent study found that CXC chemokine ligand 13 and galectin-9 could be prognostic biomarkers of progression-free survival and treatment response in patients with chronic lymphocytic leukemia.
RP2 demonstrated promising response rates and tolerability in the treatment of metastatic uveal melanoma, both as a monotherapy and in combination with nivolumab.
The combination of and investigational immune checkpoint inhibitor, immunotherapy, and antibody-drug conjugate showed improvements in overall survival in patients with a variety of human papillomavirus-positive cancers.
THIO has received 2 prior orphan drug designations, and the agent has shown promise in preclinical studies for the treatment of glioblastoma.
In patients with metastatic castration-resistant prostate cancer of the adenocarcinoma phenotype, the combination of BXCL701 and pembrolizumab led to a median overall survival of 15.5 months.
The updated indication limits the use of pembrolizumab and chemotherapy to tumors expressing PD-L1 as determined by an FDA-approved test.
The combination of SRK-181 and pembrolizumab demonstrated improvements in objective response rate among patients with clear cell renal cell carcinoma in a phase 1 proof-of-concept study.
Selinexor maintenance therapy shows potential in bettering survival compared with placebo in patients with TP53 wild-type recurrent or advanced endometrial cancer.
Findings from the phase 2 RAMP 201 trial show avutometinib plus defactinib demonstrates robust efficacy in patients with recurrent low-grade serious ovarian cancer.
Retrospective data shows that a multidisciplinary surgical approach may improve survival in patients with ovarian cancer.
The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.
According to findings presented at the Connective Tissue Oncology Society Annual Meeting, INT230-6 enhanced overall survival and disease control rates in relapsed, refractory, and metastatic sarcomas.
In the KEYNOTE-564 trial, patients with renal cell carcinoma who had a nephrectomy achieved improved overall survival rates vs placebo when treated with adjuvant pembrolizumab.
The FDA accepted the new drug application and granted priority review to tovorafenib with a Prescription Drug User Fee Act target date of April 30, 2024.
A phase 2 clinical trial has demonstrated the potential of zanubrutinib combined with R-CHOP for the treatment of untreated diffuse large B-cell lymphoma with extranodal involvement.
SLS009 showed promising efficacy in a phase 1 trial and now has been granted a fast track designation by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma.
While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
The investigational agent is undergoing evaluation in a phase 1/2 trial for the treatment of relapsed or refractory metastatic castration-resistant prostate cancer resistant to androgen receptor pathway inhibitors.